Clinical Trials Directory

Trials / Completed

CompletedNCT04669626

The Ability of Octenilin® to Reduce Odour of Malodorous Wound

The Ability of Octenilin® to Reduce Odour of Malodorous Wound - a Single-center Randomized Double Blinded Controlled Pilot Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
School of Health Sciences Geneva · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Malodours are a common complication of chronic wounds. They are the result of the proliferation of aerobic and anaerobic micro-organisms on the wound surface, where they metabolize healthy tissue which leads to the production of sloughy and even necrotic tissue. Wound odour has a big impact on the quality of life of patients. Currently the standard of care for the management of malodourous wounds are systemic antibiotics, absorbent wound dressings with or without activated carbon and, topical antimicrobials. The application of topical antimicrobials such as antiseptics against wound odour is part of the standard care. One suggested antiseptic in a recent published standard is Octenilin®. There is ample anecdotal evidence about the efficacy of Octenilin® in reducing wound odour. Therefore, we propose here to document this ability by evaluating the odour of wounds washed with Octenilin® versus standard care (NaCl 0.9% solution).

Detailed description

Malodours are a common complication of chronic wounds. They are the result of the proliferation of aerobic and anaerobic micro-organisms on the wound surface, where they metabolize healthy tissue which leads to the production of sloughy and even necrotic tissue. Wound odour has a big impact on the quality of life of patients. Patients describe living with a chronic malodourous wound as devastating particularly in respect to social interaction. The key to addressing the negative consequences of malodorous and/or discharging wounds is an effective wound managements plan based on accurate and holistic assessment of the patient and the wound. Currently the standard of care for the management of malodourous wounds are systemic antibiotics, absorbent wound dressings with or without activated carbon and, topical antimicrobials. The application of topical antimicrobials such as antiseptics against wound odour is part of the standard care. One suggested antiseptic in a recent published standard is Octenilin®. Octenilin® wound cleansing solution is on the Swiss market since 2006 and is routinely used in outpatient wound care centers. It exhibits good performance in the reduction of biofilm's pathogens and has excellent moisturizing properties. While there is ample anecdotal evidence about the efficacy of Octenilin® in reducing wound odour, we propose here to document this ability by evaluating the odour of wounds washed with Octenilin® versus standard care (NaCl 0.9% solution).

Conditions

Interventions

TypeNameDescription
OTHERUse of OcetnilinVisits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows: * Removal of old dressing * Applying a soaked gaze with Octenilin® on the wound (5 minutes) * Mechanical debridement if necessary * Wound cleansing with Octenilin® * Application of new dressing (according to the wound healing phases, medical prescription)
OTHERUse of NaCl 0.9%Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows: * Removal of old dressing * Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes) * Mechanical debridement if necessary * Wound cleansing with NaCl 0.9% solution * Application of new dressing (according to the wound healing phases, medical prescription)

Timeline

Start date
2020-07-01
Primary completion
2021-11-30
Completion
2021-12-22
First posted
2020-12-17
Last updated
2022-05-11

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT04669626. Inclusion in this directory is not an endorsement.